Energenesis Biomedical, founded in 2012, is a biotech company publicly listed on the Taiwan Stock Exchange Corporation (TWSE: 6657) in 2023. With over a decade of commitment, our team has pioneered the ENERGI-Platform, a novel approach using small molecule drugs to boost cellular energy levels. This technology activates self-healing mechanisms within cells, empowering us to explore innovative ways of addressing challenging diseases.

Pipeline:

ENERGI-F703DFU: gel for Diabetic foot ulcers (Phase III, recruiting in the US and Taiwan)

ENERGI-F701: hair tonic for Alopecia (Phase II, completed)

ENERGI-F703EB: cream for Epidermolysis Bullosa (in preparation for Phase II, granted ODD&RPD)

ENERGI-F705PD : oral medicine for Parkinson’s disease (in preparation for Phase II)

Energenesis Biomedical

Org chart

Teams

Offices